A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

PHASE3TerminatedINTERVENTIONAL
Enrollment

3,232

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Coronary Artery Disease
Interventions
DRUG

pegnivacogin/anivamersen

DRUG

Bivalirudin

Trial Locations (1)

57701

Black Hills Cardiovascular Research, Rapid City

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

Duke Clinical Research Institute

OTHER

collaborator

Canadian VIGOUR Centre

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Parexel

INDUSTRY

lead

Regado Biosciences, Inc.

INDUSTRY